{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:47:04Z","timestamp":1761518824612},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"S1","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Capecitabine has proven efficacy in metastatic breast cancer, extending survival in combination with docetaxel and offering a favorable safety profile, including minimal myelosuppression and alopecia, as a single agent. It is therefore logical that capecitabine could build on the improved out come sachieved with taxanes in early breast cancer. In the neoadjuvant setting, a phase III trial of capecitabine and docetaxel (XT) versus doxorubicin and cyclophosphamide (AC) showed that XT was more effective than AC in terms of clinical response rate and pathologic complete response rate, with a manageable safety profile. Other studies, including a phase III trial of capecitabine, epirubicin, and docetaxel, a phase III trial of capecitabine and vinorelbine, and several phase II studies of different regimens with capecitabine, have confirmed the high activity of neoadjuvant capecitabine, with acceptable safety. In the adjuvant setting, a Finnish phase III study (FinXX) of sequential XT followed by cyclophosphamide, epirubicin, and capecitabine versus docetaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide has shown favorable safety with lower doses of both capecitabine and docetaxel in the XT combination. Efficacy results from that trial are eagerly awaited. A large, ongoing trial program is continuing to explore the potential for capecitabine in the treatment of early breast cancer, looking at capecitabine\u2013taxane combinations, capecitabine maintenance therapy, capecitabine for elderly patients, and sequential versus combination therapy, involving &amp;gt;20,000 patients.<\/jats:p>","DOI":"10.1634\/theoncologist.11-90001-20","type":"journal-article","created":{"date-parts":[[2006,9,14]],"date-time":"2006-09-14T01:12:26Z","timestamp":1158196346000},"page":"20-26","source":"Crossref","is-referenced-by-count":10,"title":["Capecitabine: Expanding Options for the Treatment of Patients with Early or Locally Advanced Breast Cancer"],"prefix":"10.1093","volume":"11","author":[{"given":"Andrew","family":"Wardley","sequence":"first","affiliation":[{"name":"Christie Hospital and South Manchester University Hospital, Manchester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2006,9,1]]},"reference":[{"key":"2021122208444193200_R1","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0140-6736(98)03301-7","article-title":"Polychemotherapy for early breast cancer: an overview of the randomised trials","volume":"352","author":"Early Breast Cancer Trialists' Collaborative Group","year":"1998","journal-title":"Lancet"},{"key":"2021122208444193200_R2","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJM199504063321401","article-title":"Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. The results of 20 years of follow-up","volume":"332","author":"Bonadonna","year":"1995","journal-title":"N Engl J Med"},{"key":"2021122208444193200_R3","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1200\/JCO.2001.19.22.4224","article-title":"Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902","volume":"19","author":"Van der Hage","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122208444193200_R4","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1200\/JCO.2003.04.576","article-title":"Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer","volume":"21","author":"Goldhirsch","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122208444193200_R5","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1517\/14656566.6.9.1477","article-title":"Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials","volume":"6","author":"Hanrahan","year":"2005","journal-title":"Expert Opin Pharmacother"},{"key":"2021122208444193200_R6","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1200\/JCO.2003.01.136","article-title":"International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations","volume":"21","author":"Kaufmann","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122208444193200_R7","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1200\/JCO.2003.05.980","article-title":"Preoperative chemotherapy for breast cancer: lessons learned and future prospects","volume":"21","author":"Sledge","year":"2003","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2021122208444193200_R8","first-page":"S16","article-title":"A randomized trial comparing pre-operative (preop) doxorubicin\/cyclophosphamide (AC) to preop AC followed by preop docetaxel (T) and to preop AC followed by postoperative (postop) T in patients (pts) with operable carcinoma of the breast: results of NSABP B-27","volume":"88","author":"Bear","year":"2004","journal-title":"Breast Cancer Res Treat"},{"key":"2021122208444193200_R9","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1056\/NEJMoa043681","article-title":"Adjuvant docetaxel for node-positive breast cancer","volume":"352","author":"Martin","year":"2005","journal-title":"N Engl J Med"},{"key":"2021122208444193200_R10","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.2002.09.002","article-title":"Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results","volume":"20","author":"O'shaughnessy","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122208444193200_R11","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S1359-6349(05)80705-0","article-title":"A single institution randomized trial of Taxotere (T) and Xeloda (X) given in combination vs. Taxotere (t) followed by Xeloda (x) after progression as first line chemotherapy (CT) for metastatic breast cancer (MBC)","volume":"3","author":"Beslija","year":"2005","journal-title":"EJC Suppl"},{"issue":"suppl 1","key":"2021122208444193200_R12","first-page":"S224","article-title":"Mature results from a randomized phase III trial of docetaxel\/capecitabine (TX) vs. doxorubicin\/cyclophosphamide (AC) as primary chemotherapy for patients (pts) with stage II\/III breast cancer (BC)","volume":"94","author":"Lee","year":"2005","journal-title":"Breast Cancer Res Treat"},{"issue":"suppl 3","key":"2021122208444193200_R13","first-page":"iii42","article-title":"Randomized phase III trial comparing TEX (docetaxel, epirubicin and capecitabine) vs. TE (docetaxel and epirubicin) in advanced breast cancer patients: findings from the 2nd interim analysis","volume":"15","author":"Mansutti","year":"2004","journal-title":"Ann Oncol"},{"issue":"suppl 1","key":"2021122208444193200_R14","first-page":"S19","article-title":"Comparison of docetaxel\/ doxorubicin\/cyclophosphamide (TAC) versus vinorelbine\/capecitabine (NX) in patients non-responding to 2 cycles of neoadjuvant TAC chemotherapy - first results of the phase III GEPARTRIO-Study by the German Breast Group","volume":"94","author":"von Minckwitz","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"2021122208444193200_R15","doi-asserted-by":"crossref","first-page":"6764","DOI":"10.1158\/1078-0432.CCR-04-0976","article-title":"A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer","volume":"10","author":"Lebowitz","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2021122208444193200_R16","first-page":"61s","article-title":"Phase II study of capecitabine (C) in combination with docetaxel (D) as neoadjuvant treatment in patients with locally advanced breast cancer (IIIA and IIIB stage)","volume":"23","author":"Bellet","year":"2005","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"2021122208444193200_R17","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1359-6349(05)80673-1","article-title":"Neoadjuvant capecitabine (X) plus docetaxel (T) for patients (pts) with locally advanced breast cancer (LABC): preliminary safety and efficacy data","volume":"3","author":"Lybaert","year":"2005","journal-title":"EJC Suppl"},{"key":"2021122208444193200_R18","first-page":"96s","article-title":"Preliminary results of a multicenter phase II trial of neoadjuvant docetaxel, carboplatin and capecitabine for inflammatory and locally advanced breast cancer (LABC)","volume":"23","author":"Franco","year":"2005","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"2021122208444193200_R19","first-page":"93s","article-title":"A phase II trial of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer","volume":"23","author":"Lu","year":"2005","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"2021122208444193200_R20","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1359-6349(05)80774-8","article-title":"Preliminary results of a phase II study of neoadjuvant treatment with docetaxel (T), doxorubicin (A) and capecitabine (X) in locally advanced or inflammatory breast cancer","volume":"3","author":"Perez-Manga","year":"2005","journal-title":"EJC Suppl"},{"key":"2021122208444193200_R21","first-page":"27","article-title":"Phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in women with locally advanced or inflammatory breast cancer","volume":"22","author":"Ahlgren","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"suppl 1","key":"2021122208444193200_R22","first-page":"S227","article-title":"Neoadjuvant capecitabine chemo-radiation (X-RT) for patients (pts) with locally advanced breast cancer (LABC) failing anthracycline-based neoadjuvant therapy: findings from a prospective phase II trial","volume":"94","author":"Gaui","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"2021122208444193200_R23","first-page":"57s","article-title":"Phase III, randomized study of docetaxel (T) + capecitabine (X) (TX) followed by cyclophosphamide (C) + epirubicin (E) + X (CEX) vs. T followed by C + E + fluorouracil (F) (CEF) as adjuvant treatment for patients (pts) with early breast cancer (BC): an interim safety analysis","volume":"23","author":"Joensuu","year":"2005","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"2021122208444193200_R24","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/sj.bjc.6600261","article-title":"Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic\/advanced breast cancer pretreated with anthracyclines","volume":"86","author":"Talbot","year":"2002","journal-title":"Br J Cancer"},{"key":"2021122208444193200_R25","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1023\/A:1012281104865","article-title":"Randomized, open-label, phase II trial of oral capecitabine (Xeloda\u00ae) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced\/metastatic breast cancer","volume":"12","author":"O'shaughnessy","year":"2001","journal-title":"Ann Oncol"},{"key":"2021122208444193200_R26","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.1999.17.2.485","article-title":"Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer","volume":"17","author":"Blum","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021122208444193200_R27","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/1097-0142(20011001)92:7<1759::AID-CNCR1691>3.0.CO;2-A","article-title":"Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients","volume":"92","author":"Blum","year":"2001","journal-title":"Cancer"},{"key":"2021122208444193200_R28","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/annonc\/mdg346","article-title":"Multicenter phase II study of oral capecitabine (Xeloda\u00ae) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy","volume":"14","author":"Reichardt","year":"2003","journal-title":"Ann Oncol"},{"key":"2021122208444193200_R29","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ejca.2003.11.007","article-title":"Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer","volume":"40","author":"Fumoleau","year":"2004","journal-title":"Eur J Cancer"},{"key":"2021122208444193200_R30","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","article-title":"Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer","volume":"23","author":"Miller","year":"2005","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.11-90001-20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.11-90001-20","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/11\/S1\/20\/41851305\/oncolo_11_s1_20.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/11\/S1\/20\/41851305\/oncolo_11_s1_20.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T15:18:31Z","timestamp":1640186311000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/11\/S1\/20\/6397128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,1]]},"references-count":30,"journal-issue":{"issue":"S1","published-online":{"date-parts":[[2006,9,1]]},"published-print":{"date-parts":[[2006,9,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.11-90001-20","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2006,9,1]]},"published":{"date-parts":[[2006,9,1]]}}}